Inspections and the observations that follow
The FDA inspects facilities across the industries it regulates, from food plants to drug and device manufacturers. At the close of an inspection the investigator may issue a Form FDA 483 listing conditions that may violate the rules the agency enforces. A 483 is not a final agency finding, but how a company responds, and how quickly, often influences whether the matter escalates to a warning letter. Responses usually need to come within a short window and should be specific about what was corrected and how it was verified. A response that promises everything and documents nothing tends to read poorly to the people who decide what happens next.
Warning letters, holds, and imports
A warning letter is published by the agency and is often read by customers, partners, and investors, so its consequences reach well past regulators. Imported products can be detained at the border, and products from a firm placed on an import alert may be held without physical examination until the company shows they meet requirements. Importers deal with both the FDA and Customs and Border Protection, which coordinate but play different roles at entry. A product held at the port runs up storage costs while paperwork is assembled. Knowing which agency is waiting on what is the first practical step toward release.
Assembling a response
We begin by reading exactly what was observed or alleged and matching each point to the company's own records, such as batch records, complaint files, test results, and corrective action reports. Often the problem is less the product than the documentation around it. Technical questions call for input from people who know the manufacturing process or the science, and we work alongside them so the response is accurate. We also consider whether the issue raises reporting obligations or customer notifications of its own. From there we outline what a credible FDA compliance response would include and what the company can realistically commit to and carry out.
